REFERENCES
- Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004; 42: 4419–31.
- Hawkins JL, Baddour LM. Candida lusitaniae infections in the era of fluconazole availability. Clin Infect Dis 2003; 36: e14–8.
- Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a per-sistent public health problem. Clin Microbiol Rev 2007; 20: 133–63.
- Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 2007; 45: 1735–45.
- Atkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and out-come. Med Mycol 2008; 46: 541–6.
- McClenny NB, Fei H, Baron EJ, Gales AC, Houston A, Hollis RJ, et al. Change in colony morphology of Candida lusitaniae in association with development of amphotericin B resistance. Antimicrob Agents Chemother 2002; 46: 1325–8.
- Favel A, Michel-Nguyen A, Peyron F, Martin C, Thomachot L, Datry A, et al. Colony morphology switching of Candida lusitaniae and acquisi-tion of multidrug resistance during treatment of a renal infection in a new-born: case report and review of the literature. Diagn Microbiol Infect Dis 2003; 47: 331–9.
- Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ, Jones RN, et al. In vitro activities of voriconazole, posaconazole, and four licensed sys-temic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78–83.
- Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans col-lected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201–5.
- Barchiesi F, Tortorano AM, Di Francesco LF, Cogliati M, Scalise G, Viviani MA. In vitro activity of five antifungal agents against uncommon cli-nical isolates of Candida spp. J Antimicrob Chemother 1999; 43: 295–9.
- Favel A, Michel-Nguyen A, Datry A, Challier S, Leclerc F, Chastin C, et al. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents. J Antimicrob Chemother 2004; 53: 526–9.
- Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. 3rd ed. Document M27-A3. Wayne, PA: CLSI; 2008.
- St-Germain G, Laverdiére M, Pelletier R, René P, Bourgault AM, Le-mieux C, et al. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 2008; 19: 55–62.
- Gonzalez GM, Elizondo M, Ayala J. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) sur-veillance study. J Clin Microbiol 2008; 46: 2902–5.
- Pfaller MA, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Diekema DJ. Evaluation of the Etest method using Mueller-Hinton agar with glucose and methylene blue for determining amphotericin B MICs for 4,936 clinical isolates of Candida species. J Clin Microbiol 2004; 42: 4977–9.